StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABSW) stock

SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30
$0.01+0.00 (+33.33%)

Close on Oct 20, 2026Market cap $304.80MP/E –Yield –

SAB Biotherapeutics shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

SAB Biotherapeutics's shares outstanding was 80M at Jun 30, 2026. For fiscal 2025 it was 61M, up 562.3% from the year before. The highest annual figure on record is 61M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 202561M+562.3%
FY2024Dec 31, 20249M+67.7%
FY2023Dec 31, 20236M+26.9%
FY2022Dec 31, 20224M-9.8%
FY2021Dec 31, 20215M+1.2%
FY2020Dec 31, 20205M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 202680M+758.3%
Q1 FY2026Mar 31, 202654M+476.4%
Q3 FY2025Sep 30, 202578M+740.9%
Q2 FY2025Jun 30, 20259M+0.4%
Q1 FY2025Mar 31, 20259M+0.5%
Q4 FY2024Dec 31, 20249M+37.4%
Q3 FY2024Sep 30, 20249M+76.7%
Q2 FY2024Jun 30, 20249M+83.6%
Q1 FY2024Mar 31, 20249M+83.4%
Q4 FY2023Dec 31, 20237M-14.8%
Q3 FY2023Sep 30, 20235M-31.0%
Q2 FY2023Jun 30, 20235M-33.6%
Q1 FY2023Mar 31, 20235M-37.7%
Q4 FY2022Dec 31, 20228M+43.1%
Q3 FY2022Sep 30, 20228M+65.7%
Q2 FY2022Jun 30, 20228M+65.6%
Q1 FY2022Mar 31, 20228M+63.2%
Q4 FY2021Dec 31, 20216M–
Q3 FY2021Sep 30, 20215M–
Q2 FY2021Jun 30, 20215M–
Q1 FY2021Mar 31, 20215M–

More SAB Biotherapeutics figures